Lipocine
LPCN
31 hedge funds and large institutions have $6.63M invested in Lipocine in 2019 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 3 closing their positions.
233% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 3
143% more capital invested
Capital invested by funds: $2.73M → $6.63M (+$3.9M)
29% more funds holding
Funds holding: 24 → 31 (+7)
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
16% more call options, than puts
Call options by funds: $66K | Put options by funds: $57K
0.13% more ownership
Funds ownership: 0.58% → 0.71% (+0.13%)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$370K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$369K |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
+$247K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
| 5 |
SIM
Spark Investment Management
New York
|
+$92.2K |
Top Sellers
| 1 |
JGC
J. Goldman & Co
New York
|
-$310K |
| 2 |
Barclays
London,
United Kingdom
|
-$39K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$9.97K |
| 4 |
MAM
Meeder Asset Management
Dublin,
Ohio
|
-$5.43K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.82K |
LPCN Hedge Fund Activity: Q1 2019 in Review
31 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2019, worth a combined $6.63M — up 143% from $2.73M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new LPCN positions and 3 closed out — a net gain of 7 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $370K. The largest seller was J. Goldman & Co, exiting entirely with an estimated $310K sold.
- 31 institutional investors held Lipocine (LPCN) as of Q1 2019, up from 24 in Q4 2018.
- Funds reported $6.63M of Lipocine stock for Q1 2019, up 143% quarter-over-quarter.
- 10 funds opened new Lipocine positions in Q1 2019 and 3 closed out, a net change of +7 holders.
- The largest Lipocine buyer in Q1 2019 was Renaissance Technologies, an estimated $370K added.
- The largest Lipocine seller in Q1 2019 was J. Goldman & Co, an estimated $310K sold.
Based on aggregated 13F filings for Q1 2019.